Document:

Form of Employment Agreement

 Exhibit 10.9 
 EMPLOYMENT AND CONFIDENTIALITY AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and
entered into effective as of [•], 2006, (the “Effective Date”), by and between 3Sbio, Inc. (the “Company”), and [•], an individual residing in [•] (the “Employee”). 
 WITNESSETH: 
 WHEREAS, the Company desires to
employ the Employee, and the Employee desires to accept such employment, on the terms and subject to the conditions set forth in this Agreement. 
 NOW,
THEREFORE, in consideration of the foregoing recitals and for other good and valuable consideration, the parties hereto covenant and agree as follows: 
  

	1.	EMPLOYMENT 

 The Company hereby employs Employee in
the position of [•], and the Employee hereby accepts such employment, upon the terms and conditions set forth in this Agreement. 
  

	2.	TERM 

 The initial term of the Employment shall be
[•] years, commencing on [•] (the “Effective Date”), until [•]. 
  

	3.	DUTIES AND RESPONSIBILITIES 

 The Employee agrees to
serve as the [•] of the Company. In this position, the Employee will be responsible for
[                                       
 ]. Employee’s duties at the Company will also include other relevant jobs assigned by the Company’s Board of the Directors (the “Board”) or the Chairman/CEO. 
 The Employee shall devote all of his or her working time, attention and skills to the performance of his or her duties and shall faithfully and diligently
serve the Company in accordance with this Agreement, and the guidelines, policies and procedures of the Company as approved from time to time by the Board. 
 The Employee shall use his or her best endeavor to perform the duties hereunder. The Employee shall not, without the prior consent of the Board, become an employee of any entity other than the Company and any
subsidiary of the Company, and shall not be concerned or interested in any other business directly competitive with that carried on by the Company. The Company shall have the sole discretion to determine, and shall notify the Employee, from time to
time, as to which other companies are deemed to be in business directly competitive with that carried on by the Company. [Notwithstanding the foregoing, nothing in this clause shall preclude the Employee from holding or being otherwise interested in
any shares or other securities of such companies that are listed on any securities exchange or recognized securities market anywhere, provided that the Employee shall notify the Company in writing of his or her existing interest in such shares or
securities in a timely manner and with such details and particulars as the Company may reasonably require, provided further that before the Employee obtains such additional interest or such additional shares, the Employee shall first notify the
Company in writing and with such details and particulars as the Company may reasonably require.] 
  

 1 

	4.	LOCATION 

 The Employee will be based in the
Company’s office in [Shenyang] or such other locations that the Company may consider necessary for carrying out his or her duties. 
  

	5.	COMPENSATION AND BENEFITS 

  

	 	(a)	Annual Salary. In consideration for the service rendered by the Employee to the Company and any of its subsidiary, the Employee’s compensation shall consist of
(X) an annual salary of [•]for the first year of the Employment, subject to annual review and adjustment by the Company in [•] every year and (Y) a discretionary performance bonus based on his or her performance.

  

	 	(b)	Stock Options. [The Employee will be entitled to participate in the stock options plan adopted by the Company.] 

  

	 	(c)	Benefits. The Employee are eligible for participation in any standard employee benefits plan of the Company that currently exists or may be adopted by the Company in the
future, including, but not limited to, any retirement plan, life insurance plan, health insurance plan and travel/holiday plan. 

  

	 	(d)	Vacation. The Employee shall be entitled to [•] weeks paid vacation each year during the term of the Employee’s employment hereunder. Unused vacation from the prior
year can [not] be carried over to the succeeding year. 

  

	 	(e)	Taxation. The Employee is responsible to report his or her compensation to relevant tax authority in accordance with relevant laws and regulations. The Company or any of its
subsidiary should report his or her compensation to relevant tax authority and withhold an adequate portion of his or her salary for the relevant tax if required by relevant laws and regulations. 

  

	 	(f)	Working Hours. The Employee shall work 8 hours per day and five days per week except on public holidays and annual paid leave, or such other numbers of working hours as
agreed between the Employee and the Company. 

  

	6.	TERMINATION OF THE AGREEMENT 

  

	 	(a)	By the Company. The Company may terminate the Employment for cause, at any time, without notice or remuneration, if (1) the Employee is convicted or pleads guilty or
nolo contendere to a felony or to an act of fraud, misappropriation or embezzlement, (2) the Employee has been negligent or acted dishonestly to the detriment of the Company, or (3) the Employee has engaged in actions amounting to
misconduct or failed to perform his or her duties hereunder and such failure continues after the Employee are afforded a reasonable opportunity to cure such failure. In addition, the Company may terminate the Employment without cause at any time. In
the case of termination by the Company without cause, the Company will pay the Employee a compensation equal to [•] months of his or her salary. 

  

 2 

	 	(b)	By Employee. The Employee may terminate the Employment at any time upon [•] months written notice to the Company, provided that, in the event that the Employee provides
less than [•] months written notice, the Employee is required to pay to the Company a damage in the amount equal to [•] months of his or her salary. 

  

	7.	CONFIDENTIALITY AND NON-DISCLOSURE 

 In the course
of the Employee’s services, the Employee may have access to the Confidential Information (as defined below) of the Company, its subsidiaries or any other third party, including but not limited to those embodied in memoranda, manuals, letters or
other documents, computer disks, tapes or other information storage devices, hardware, or other media or vehicles, pertaining to the businesses of the Company, its subsidiaries or such other third party. All materials containing any such
Confidential Information are the property of the Company, its subsidiaries, and/or such third party, and shall be returned to the Company, its subsidiaries, and/or such third party upon expiration or earlier termination of this Agreement. The
Employee shall not directly or indirectly disclose or use any such Confidential Information, except as required in the performance of his or her duties in connection with the Employment. 
 During and after the Employment, the Employee shall hold the Confidential Information in strict confidence; the Employee shall not disclose the
Confidential Information to anyone except other employees of the Company who have a need to know the Confidential Information in connection with the Company’s business. The Employee shall not use the Confidential Information other than for the
benefits of the Company. 
 “Confidential Information” means information deemed confidential by the Company and its subsidiaries,
treated by the Company and its subsidiaries or which the Employee knows or ought reasonably to have known to be confidential, and trade secrets, including without limitation designs, processes, pricing policies, methods, inventions, conceptions,
technology, technical data, financial information, corporate structure and know-how, relating to the business and affairs of the Company and its subsidiaries, affiliates and business associates, whether embodied in memoranda, manuals, letters or
other documents, computer disks, tapes or other information storage devices, hardware, or other media or vehicles. Confidential Information does not include information generally known or released to public domain through no fault of the Employee.

 This Section 7 shall survive the termination of this Agreement for any reason. 
  

	8.	INVENTIONS ASSIGNMENT 

 The Employee understands
that the Company and its subsidiaries are engaged in research and development and other activities in connection with its business and that, as an essential part of the Employment, the Employee is expected to make new contributions to and create
inventions of value for the Company and its subsidiaries. 
  

 3 

 From and after the Effective Date, the Employee shall disclose in confidence to the Company and its
subsidiaries all inventions, improvements, designs, original works of authorship, formulas, processes, compositions of matter, computer software programs, databases, mask works and trade secrets (collectively, the “Inventions”), which the
Employee may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of his or her employment at the Company. The Employee acknowledges that copyrightable works
prepared by him or her within the scope of and during the period of his or her employment with the Company are “works for hire” and that the Company and its subsidiaries will be considered the author thereof. The Employee agrees that all
the Inventions shall be the sole and exclusive property of the Company and its subsidiaries and the Employee hereby assigns all his or her right, title and interest in and to any and all of the Inventions to the Company and its subsidiaries or its
successor in interest without further consideration. 
 The Employee agrees to assist the Company and its subsidiaries in every proper way to
obtain for the Company and its subsidiaries and enforce patents, copyrights, mask work rights, trade secret rights, and other legal protection for the Inventions. The Employee will execute any documents that the Company and its subsidiaries may
reasonably request for use in obtaining or enforcing such patents, copyrights, mask work rights, trade secrets and other legal protections. His or her obligations under this paragraph will continue beyond the termination of his or her employment
with the Company, provided that the Company will compensate the Employee at a reasonable rate after such termination for time or expenses actually spent by the Employee at the Company’s request on such assistance. The Employee appoints the
Secretary of the Company as his or her attorney-in-fact to execute documents on his or her behalf for this purpose. 
 This Section 8
shall survive the termination of this Agreement for any reason. 
  

	9.	NON-COMPETITION 

 In consideration of the salary
paid to the Employee by the Company, the Employee agrees that during the term of the Employment and for a period of [•] years following the termination or expiration of this Agreement (for whatever reason): 
  

	 	(a)	the Employee will not approach clients, customers or contacts of the Company or other persons or entities introduced to the Employee in his or her capacity as a representative of
the Company for the purposes of doing business with such persons or entities and will not interfere with the business relationship between the Company and such persons and/or entities; 

  

	 	(b)	unless expressly consented to by the Company, the Employee will not assume employment with or provide services as a director or otherwise for any competitor of the Company, or
engage, whether as principal, partner, licensor or otherwise, in any business which is in direct or indirect competition with the business of the Company and its subsidiaries; and 

  

 4 

	 	(c)	unless expressly consented to by the Company, the Employee will not seek directly or indirectly, by the offer of alternative employment or other inducement whatsoever, to solicit
the services of any employee of the Company and its subsidiaries employed as at or after the date of such termination, or in the year preceding such termination. 

 The provisions provided in Section 9 shall be separate and severable, enforceable independently of each other, and independent of any other provision
of this Agreement. 
 The provisions contained in Section 9 are considered reasonable by the Employee and the Company but, in the event
that any such provisions should be found to be void under applicable laws but would be valid if some part thereof was deleted or the period or area of application reduced, such provisions shall apply with such modification as may be necessary to
make them valid and effective. 
 This Section 9 shall survive the termination of this Agreement for any reason. 
  

	10.	ENTIRE AGREEMENT 

 This Agreement constitutes the
entire agreement and understanding between the Employee and the Company regarding the terms of the Employment. The Employee acknowledges that the Employee has not entered into this Agreement in reliance upon any representation, warranty or
undertaking which is not set forth in this Agreement. Any amendment to this Agreement must be in writing and signed by the Employee and the Company. 
  

	11.	GOVERNING LAW 

 This Agreement shall be governed by
and construed in accordance with the laws of [PRC]. 
 IN WITNESS WHEREOF, this Agreement has been executed. 
  

			
	3Sbio Inc.	 	Employee
		
	Signature:                    	 	Signature:                    
		
	Name:	 	Name:
	Title:	 	

  

 5National Agency Agreement, dated as of May 1, 2006 and supplementary memo

 Exhibit 10.10 
 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
 English translation of the executed copy

 National Agency Agreement for Tietai 
 Party A:
Shenyang Borui Pharmaceutical Co., Ltd 
 Party B: Liaoning Sunshine Pharmaceutical Co., Ltd 
 In accordance with the relevant Chinese laws and regulations, Chengdu Borui Pharmaceutical Technology and Development Co., Ltd (hereinafter referred to as Party A) and Liaoning Sunshine Pharmaceutical Co., Ltd
(hereinafter referred to as Party B), for the purpose of taking full advantages of each party and exploiting more market opportunities, have reached this agreement on the basis of mutual benefits and common development through friendly negotiations
of both parties. 
  

	1.	Party A entrusts Party B to take charge of selling and marketing Party A’s product Tietai (Iron Sucrose Injection) as the national sole agent. Party A shall not sell this
product to any third-party during the term of this agreement. 

  

	2.	The specifications of the product contemplated hereunder (hereinafter referred to as the Product, the prices include tax, denominated in RMB Yuan): 

  

													
	 Name
	  	Specifications	  	Unit	  	 Wholesale
 Price
	  	 Retail
 Unit Price
	  	Supply
Unit Price	  	 Best
 before

	 Tietai Iron Sucrose Injection
	  	0.1g Iron & 1.6g
Sucrose: 5 ml	  	Dose	  	85.21	  	98	  	***	  	Within 2 years

  

	3.	Agency Period: from May 1st, 2006 to July 30th, 2011, during which a period starting from May 2006 to July 2006 shall be the period for market succession and no sales target shall
be imposed. 

  

	4.	Market succession. Market succession shall take place within three months after the date of this agreement. During such period, Party A shall provide the signed regional agency
agreement and assist Party B in its coordination with existing regional agents. Party B may continue to retain those regional agents in those regions where such agency is well-performed or withdraw the same through mutual consultations after due
compensation. Those regional agents that have failed to perform its agency shall be terminated as provided thereunder and the sales in such region shall be taken over by Party B. All the inventories at the place of the agents, commercial sites and
hospitals shall be recorded as Party B’s sales volume after the succession period. 

  

 1 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
  

	5.	The sales target and schedule of the agency: 

  

	 	1)	Party B shall guarantee its purchase quantity up to 300,000 pieces of injection, with 30,000 pieces as the first purchase from August 2006 to July 2007 (i.e. the first agency year).

  

	 	2)	The sales target of the second agency year will be agreed upon as supplemental provisions hereto through the consultations of both parties within 6 months after date of this
agreement. 

  

	 	3)	The annual sales target of the years during the rest of the agency period will be determined according to, among other things, the sales volume of the previous year, the market
potentials and developments, and will be written into the supplemental provisions hereto through the consultations of both parties. 

  

	6.	The deposit and its use: After signing this agreement, Party B will pay RMB *** as deposit. The deposit shall be used as follows: 

  

	 	1)	In connection with assessment of the sales volume (periodical sales targets, periodical IMS market share): 

 If Party B achieves more than 90% of the sales target in the first agency year, the deposit will not be deducted by the Party A. If Party B achieves less
than 90% but more than 60% of the sales target, the deposit will be deducted pro rata based on the unachieved sales volume. For instance, if Party B achieves 80% of the sales target, then 20% of the deposit will be deducted. If Party B achieves no
more than 60% of the sales target, all its deposit will be deducted. 
 At the same time Party B shall make up for the deducted part of
deposit upon to RMB ***. 
 In the following agency year, if Party B over-fulfils the sales target and the over-fulfilled part of sales volume
(over the annual sales target of that year) set offs the unachieved part of sales volume in the first agency year or its previous year, Party A shall refund the deducted deposit to Party B. 
 If Party B fulfills the annual sales target at least for two consecutive agency years, Party A shall refund all the deposit (including the deducted part)
to Party B on the day of such achievement and shall not charge deposit from Party B again during the rest of the agency period. 
 If the
medical market is adversely affected by any change of government regulations and government guided prices, and consequently causes Party B’s failure to achieve the annual sales target, Party A shall take the circumstances into consideration and
reduce the deduction of deposit. 
  

 2 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
 If IMS data indicates that Tietai has no less than the second largest market share for the like products (vena iron preparations), Party A shall take the
circumstances into consideration and reduce the deduction of deposit. 
  

	 	2)	Party B’s breach of agreement in other aspects. 

  

	 	3)	Party B shall comply with the Chinese national laws and regulations. 

  

	 	4)	Party B shall favorably hand over the markets upon the expiry of the agency period. 

  

	7.	No credit facility. Payment shall be made by the parties upon delivery. 

  

	8.	Delivery terms: 

  

	 	1)	Party B shall fill the purchase form affixed with Party B’s seal or contract seal and fax the same together with the TMO telegraph money order to Party A.

  

	 	2)	Party A shall deliver the product to the place designated by the Party B within 3 working days after receipt of the payment and ensure that the product be received by Party B within
10 days. 

  

	 	3)	If Party B places the order one month in advance, Party A shall guarantee that the shelf period of the product is no less than 21 months. In other circumstances, the shelf period of
the product shall be no less than 18 months. 

  

	9.	The rights and duties of both parties: 

  

	 	1)	The rights and duties of Party A: 

  

	 	a.	The quality of the product supplied by Party A shall be in accordance with the national quality standards. If any economic or legal liabilities result from the bad quality of the
product, Party A shall unconditionally refund Party B and recall the bad quality product. 

  

	 	b.	Party A is prohibited from supplying the Product to other unit or individual in the agency region of Party B. If it happens, Party A shall compensate Party B an amount equivalent to
the retail unit price listed above multiplied by average sales volume in the respective region to Party B, and shall also cease such act immediately. Party A shall indicate the product number on the packing of the product (large size and middle
size) for ease of management by Party B. 

  

 3 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 

	 	c.	Party A has the responsibility to provide the full essential information, including without limitation the approval certificate of the product, new medicine certificate, information
relating to the local commodity prices and enterprises’ GMP, non-market-oriented tendentious data, in each case relating to the product and its manufacturer to Party B for market exploitation of the product. 

  

	 	d.	Party A has the responsibility to promptly provide the product index and the files and information of the medical insurance to Party B. 

  

	 	e.	Party A has the responsibility to ensure the safe delivery of the product. After the confirmation of the logistic company, Party B may request for any damages caused by the improper
delivery from Party A in 15 days after receipt of the product. 

  

	 	f.	If Party A needs to do clinic experiments for scientific research, it shall consult with Party B and formulate plans jointly. 

  

	 	2)	The rights and duties of Party B: 

  

	 	a.	Party B shall do all its best to exploit the relevant market and fulfill the sales target set herein. Party B has right to freely develop its own sales methods.

	 	b.	Party B shall be responsible for the price, medical insurance and public biding of the product. 

  

	 	c.	Party B has the responsibility to send market feedback and the use of the product to Party A and keep Party A duly informed of the market conditions of the product.

  

	 	d.	Party B shall legally manage and keep in confidence the product technology information offered by Party A. Party B shall be liable for any violation of the laws or disclosure of
confidential information in breach of this agreement. 

  

	 	e.	Party B shall consult with Party A if it needs to take clinic experiments for extending the market and formulate plans jointly. The samples needed in the clinic experiments shall be
supplied by Party A, and all copyrights of the clinic observation results, research papers, relevant books belong to Party A. Party B has the access to use them during the agency period. 

  

	 	f.	Party B will have the priority to renew the contract and obtain the agency of other new products, provided that it can duly perform this agreement and achieve the sales target set
herein. 

  

 4 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
  

	10.	Both parties need to organize the special consultation team for the mutual communication and information exchange, and notify or report in writing to the sales principals of both
parties. 

  

	11.	Termination of the agreement: 

 Any party has the right to
terminate this agreement if: 
  

	 	1)	The agreement can not be performed because of any force majeure; 

  

	 	2)	Party A has the right to terminate this agreement if Party B violates Article 5 herein and fail to fulfill the sales task or achieve the sales target. 

  

	 	3)	Party A has the right to terminate this agreement if Party B sells similar competitive product in the agent regions. 

  

	 	4)	Party B has the right to terminate this agreement if the quality problems of the product supplied by Party A have damaged the interests of Party B. 

 Any party terminating this agreement according to the above conditions shall notify the other party in writing. The date of the termination will be the
day that the termination notice is received by the other party. 
  

	12.	Incentive scheme: If Party B successfully achieves the sales target by 100%, Party A will pay Party B RMB One Yuan per piece as bonus for the over-fulfilled sales part. These prizes
can be used as the payment for the product or in the form of return of profit. 

  

	13.	Liabilities for breach of contract: Both parties shall comply with each of the provisions under this agreement. Any party in breach of this agreement shall be liable for any damages
of the other party subject to arbitration at the other party’s domicile. 

  

	14.	For any issue not covered herein, the parties can negotiate by mutual benefit to an agreement and sign supplemental agreements. If agreement is not made and dispute is caused, such
dispute shall be settled by the court or arbitral committee at the place where this agreement is signed. 

  

	15.	This agreement is signed in duplicate and each party shall keep one copy. This agreement shall be effective when it is sealed by both parties and Party B starts the purchase.

  

 5 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
 Party A: Shenyang Borui Pharmaceutical Co., Ltd 
 Legal representative: 
 Authorized Agent: /s/ Gang Wu 
 Address: 
 Zip code: 
 Tel: 
 Fax: 
 (Sealed by Shenyang Borui Pharmaceutical Co., Ltd) 
 Party B: Liaoning Sunshine Pharmaceutical Co., Ltd

 Legal representative: 
 Authorized Agent: /s/ Hognbing Wei 
 Address: 
 Zip code: 110027 
 Tel: 024-25811820 
 Fax: 024-25811821 
 (Sealed by Liaoning
Sunshine Pharmaceutical Co., Ltd) 
  

 6 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
 National Agency Agreement of Tietai 
 Supplemental Memo 
 Party A: Shenyang Borui Pharmaceutical Co., Ltd 
 Party B: Liaoning Sunshine Pharmaceutical Co., Ltd 
 The following supplemental memo is reached by the both parties on the
basis of the National Agency Agreement of Tietai. 
  

	1.	The term of the agency agreement is from June 1st, 2006 to Aug 31st, 2011. The first two months therein shall be market succession period and
consequently the terms under the agency agreement shall be extended for one month. 

  

	2.	The agreement shall be effective upon Party A’s receipt of Party B’s deposit. The first purchase quantity is 15,000 pieces. 

  

	3.	Within one week after the effectiveness of the agreement, Party A shall duly provide the following information to Party B: 

  

	 	1)	the delivery details after the product is launched into the market, including, among other things, the date, name of the customers, quantities, prices, and approval number.

  

	 	2)	copies of the contracts or agreements that Party A signed with the regional agents and the contact information including, among other things, name, address and telephone number of
each regional agent. 

	 	3)	detailed information about the bidding, winner of the bidding, bidding prices for places where the bidding process has been launched, and the existing price information (retail
prices). 

  

	4.	During the market succession period, both parties shall confirm the inventories at the place of the regional agents, dealers and hospitals. The data of the inventories shall be
confirmed by regional agents and Party B by signature and seal. Consumption of the inventories shall be subject to agreement between Party A and regional agents. 

  

	5.	Party B shall provide monthly, regional and annual sales plan (sales target) to Party A at the 4th month after the date of this agreement. 

  

	6.	Both parties shall confirm their representatives that are in charge of this project and his contact information, so as to ensure smooth communication about the logistics, quality,
sales and marketing between each party as soon as possible. 

  

 7 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
  

	7.	Party B shall place the order one month in advance so as to ensure timely production by Party A to avoid product shortage on the market. Meanwhile, Party A shall have a reasonable
stock of 20,000 pieces. 

  

	8.	Any regional agent that signed the contracts with Party A shall maintain the agency after the confirmation of the three parties. In this case, Party A should transfer the deposit
obtained from the regional agent to Party B. 

  

	9.	This agreement constitutes a supplementary document to the National Agency Agreement of Tietai. If any conflict exists between these two agreements, this agreement shall prevail.

 Party A: Shenyang Borui Pharmaceutical Co., Ltd 
 Legal representative: 
 Authorized Agent: 
 Address: 
 Zip code: 
 Tel: 024-24159443 
 Fax: 024-24159533

 (Sealed by Shenyang Borui Pharmaceutical Co., Ltd) 
 Party B: Liaoning Sunshine Pharmaceutical Co., Ltd 
 Legal representative: 
 Authorized Agent: 
 Address: 
 Zip code: 110027 
 Tel: 024-25811820

 Fax: 024-25811821 
 (Sealed by
Liaoning Sunshine Pharmaceutical Co., Ltd) 
  

 8 

 CONFIDENTIAL TREATMENT 
  

 B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]